Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 17/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 17/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 4/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612650 | 0.91 | CDK2 (0.67) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22612637 | 0.90 | CDK2 (0.55) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22612603 | 0.85 | CDK2 (0.55) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22612596 | 0.85 | CDK2 (0.55) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22624393 | 0.84 | CDK2 (0.48) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22612620 | 0.84 | CDK2 (0.50) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22612623 | 0.83 | CCNA2 (0.57) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22624289 | 0.82 | CDK2 (0.48) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22612617 | 0.81 | CDK2 (0.48) | CDK2CCNE1CCNA2CCNA1MAPK1 | |
| SCHEMBL22624397 | 0.81 | CDK2 (0.48) | CDK2CCNE1CCNA2CCNA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-13 | — | — | US | claimed |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | claimed |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-13 | — | — | US | disclosed |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2020-11-05 | — | — | US | disclosed |
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223469-A1 | N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347067-A1 | TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | CDK2 1/4885CCNE1 38/4885CCNA2 14/4885 |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | CDK2, CDK1, CCNI | CDK2 1/4885CCNE1 38/4885CCNA2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.